Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Stock Chart & Stats
$15.50
-$0.28(-2.38%)
At close: 4:00 PM EST
$15.50
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $16.74
Previous CloseN/A
Volume73.34K
Average Volume (3M)729.79K
Market Cap
$944.63M
Enterprise Value$840.71M
Total Cash (Recent Filing)$332.60M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 05, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding59,076,260
10 Day Avg. Volume883,120
30 Day Avg. Volume729,790
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.06K
Enterprise Value/Ebitda-3.56
Forecast
1Y Price Target
$31.67Price Target Upside104.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$24.43M
Bulls Say, Bears Say
Bulls Say
Autoimmune Program PotentialPhase 1 observations for the CD19xCD3 candidate indicate rapid and sustained B-cell depletion in blood and tissue with preliminary signs of activity in autoimmune diseases, which could translate into a differentiated treatment option across multiple indications.
Oncology Clinical EfficacyEarly clinical results for the FLT3-targeted candidate show meaningful responses and durable remissions in difficult-to-treat acute myeloid leukemia, including activity in TP53-mutated patients, which could support first- or best-in-class positioning if confirmed.
Partnership And Commercial StrategyThe collaboration with Taiho, including U.S. development cost-sharing and an option to co-commercialize the EGFR exon20 program, creates a clearer regulatory and commercial pathway that could accelerate revenue generation if approval is obtained.
Bears Say
Competitive Risk In EGFR Lung CancerA competing EGFR therapy that can be used as a single-agent in the first-line setting could be preferred by clinicians and limit market adoption of the exon20 targeting drug despite regulatory progress.
Dose Escalation And Data UncertaintyOngoing dose-escalation readouts, particularly at higher planned doses and durability endpoints, introduce significant outcome uncertainty that could materially affect valuation if results disappoint.
Operational And Market RisksSlow trial enrollment, the possibility of negative efficacy or regulatory outcomes, investor impatience, and potential future share dilution represent key risks that could pressure the stock.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $944.63M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Mar 05, 2026 which is in 2 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Nov 06, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.947 by $0.177.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.81.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 59,076,260 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.947. Following the earnings report the stock price went up 0.547%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.67 (104.32% Upside)
$31.67 (104.32% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $945.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.02%
12-Months-Change
Fundamentals
Return on Equity
-40.18%
Trailing 12-Months
Asset Growth
-25.89%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$31.67
▲(104.32% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---